Decipher Labs posts ₹14.1 crore Q2 FY27 consolidated loss

Decipher Labs Limited reported a consolidated net loss of ₹14.1 crore for the quarter ended September 30, 2026, while revenue from operations fell 27.9% year on year to ₹3.1 crore. The results matter because the loss widened sharply from ₹2.2 crore in the preceding quarter despite a sequential rise in revenue.

What did Decipher Labs report for Q2 FY27?

Decipher Labs reported consolidated revenue from operations of ₹3.1 crore in Q2 FY27, compared with ₹2.4 crore in Q1 FY27 and ₹4.3 crore in Q2 FY26. This indicates a sequential increase in quarterly revenue but a year-on-year decline of 27.9%.

The company recorded a net loss of ₹14.1 crore for the September quarter, against a loss of ₹2.2 crore in the June quarter. Profit before exceptional items and tax was also a loss of ₹14.1 crore, while the reported operating margin was negative 454.8%. Other income was reported at nil, compared with ₹0.1 crore in Q1 FY27.

Why do the standalone and consolidated figures differ?

The standalone and consolidated numbers differ because they reflect different reporting bases. The disclosed standalone revenue for the September quarter was ₹0.0981 crore, equivalent to ₹9.81 lakh, compared with ₹0.088 crore, or ₹8.80 lakh, in the previous quarter. The standalone quarterly loss was ₹0.1369 crore, equivalent to ₹13.69 lakh.

The consolidated financial statements, which include the group-level position, showed a much larger Q2 revenue figure of ₹3.1 crore and a loss of ₹14.1 crore. For the half-year ended September 30, 2026, consolidated revenue was stated at ₹5.4806 crore, or ₹548.06 lakh, with consultancy services identified as a contributor to revenue growth. Investors should avoid comparing standalone and consolidated figures as if they represent the same reporting perimeter.

The available disclosures also show that Decipher Labs operates in pharmaceutical products and allied services. Its business description includes manufacturing, marketing, selling and trading pharmaceutical drugs in India and international markets. The reference to consultancy services in the half-year disclosure adds context to the reported consolidated revenue base.

What did the board approve on November 14?

The board approved Decipher Labs' unaudited standalone and consolidated financial results for the quarter and half-year ended September 30, 2026, at its meeting on November 14, 2026. It also approved the related limited review reports, according to the company disclosure.

The meeting had been scheduled to consider the September-quarter and first-half results along with the standalone and consolidated review reports. The company stated that the board meeting concluded at 4:00 PM on November 14. The approval makes the Q2 and half-year financial data part of the company's formal board-reviewed disclosures.

A limited review is distinct from a full-year audit and is commonly associated with interim financial reporting. The disclosure does not provide further details on the drivers behind the Q2 loss, the composition of costs, exceptional items or future operating plans. Therefore, the reported figures should be assessed alongside subsequent company filings when they become available.

How does Q2 compare with Decipher Labs' earlier performance?

The Q2 outcome shows a mixed revenue trend and a materially higher quarterly loss. Consolidated revenue rose from ₹2.4 crore in Q1 FY27 to ₹3.1 crore in Q2 FY27, but remained below the ₹4.3 crore reported in Q2 FY26. The net loss widened from ₹2.2 crore in Q1 FY27 to ₹14.1 crore in Q2 FY27.

For FY26, Decipher Labs had reported a net loss of ₹3.08 crore, compared with a loss of ₹5.08 crore in FY25. FY26 sales were ₹14.05 crore, down from ₹22.61 crore in FY25. These historical figures show that revenue and profitability have been uneven, with losses continuing even as the company had reduced its full-year loss in FY26.

No share-price reaction, management commentary or earnings outlook was included in the supplied disclosures. As a result, the reported market impact is limited to the financial data itself: the September-quarter loss was substantially larger than the immediately preceding quarter, and the year-on-year revenue comparison remained negative.

Conclusion

Decipher Labs' Q2 FY27 consolidated result combined a sequential improvement in revenue with a sharp increase in net loss. Revenue from operations reached ₹3.1 crore, up from ₹2.4 crore in Q1 FY27, but fell from ₹4.3 crore a year earlier, while the reported loss widened to ₹14.1 crore.

The next relevant disclosures will be those that clarify the reasons for the Q2 loss, the cost structure behind the negative margin and the progression of consolidated revenue after the ₹5.4806 crore reported for the first half of FY27. Investors will also need to distinguish between standalone and consolidated results when reviewing future announcements.